Form 10-Q · Quarterly report
Thermo Fisher Scientific 10-Q, filed Oct 30, 2026
- Filed
- CIK
- 0000097745
- Accession no.
- 0000097745-26-000179
Summary
Thermo Fisher Scientific reported third-quarter 2026 revenues of $12.137 billion, up 9% year over year, with GAAP diluted EPS of $4.64 and adjusted EPS of $6.68, and said organic revenue growth was 6% for the quarter. The company also said it acquired Clario Holdings, Inc. in March 2026, sold its microbiology business to Astorg in August 2026, and acquired Solventum Corporation's filtration and separation business in September 2025.
Key points
- Third-quarter 2026 GAAP operating income was $2.263 billion and adjusted operating income was $2.968 billion; GAAP operating margin was 18.6% and adjusted operating margin was 24.5%.
- Organic revenue growth was 6% for the third quarter of 2026 and 4% for the first nine months of 2026.
- Revenue grew across all major geographies in the third quarter of 2026, with strong growth in North America and Europe and very strong growth in Asia-Pacific, including China.
- Thermo Fisher Scientific acquired Clario Holdings, Inc. within its Laboratory Products and Biopharma Services segment on March 24, 2026, and sold its microbiology business to Astorg on August 12, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The company’s operations fall into four segments (Note 11): Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.